Novo Nordisk A/S has highlighted a straightforward reality: the weight loss drug boom is far from reaching its peak.

The company's CEO, Mike Doustdar, stated that demand significantly exceeds the current supply capacity of the industry. In the United States alone, tens of millions of people are affected by obesity, yet only a small fraction are currently receiving treatment. Even with blockbuster drugs like Wegovy and Ozempic, and increasing competition from Eli Lilly, the market still appears largely untapped.

This is beginning to reshape Novo Nordisk's approach to growth. The company is preparing to significantly reduce prices in the U.S. market, anticipating price cuts of approximately 50% for Wegovy and around 33% for Ozempic starting next year. The rationale is simple: lower prices will attract more patients. At the same time, competition is intensifying. Eli Lilly is advancing its own weight loss pill, and following the loss of exclusivity for semaglutide, generic versions have begun to appear in markets such as India and China.